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Abstract
Background: Amongst the Plasmodium species in humans, only P. vivax and P. ovale produce latent hepatic stages called
hypnozoites, which are responsible for malaria episodes long after a mosquito bite. Relapses contribute to increased
morbidity, and complicate malaria elimination programs. A single drug effective against hypnozoites, primaquine, is
available, but its deployment is curtailed by its haemolytic potential in glucose-6-phosphate dehydrogenase deficient
persons. Novel compounds are thus urgently needed to replace primaquine. Discovery of compounds active against
hypnozoites is restricted to the in vivo P. cynomolgi-rhesus monkey model. Slow growing hepatic parasites reminiscent of
hypnozoites had been noted in cultured P. vivax-infected hepatoma cells, but similar forms are also observed in vitro by
other species including P. falciparum that do not produce hypnozoites.
Methodology: P. falciparum or P. cynomolgi sporozoites were used to infect human or Macaca fascicularis primary
hepatocytes, respectively. The susceptibility of the slow and normally growing hepatic forms obtained in vitro to three
antimalarial drugs, one active against hepatic forms including hypnozoites and two only against the growing forms, was
measured.
Results: The non-dividing slow growing P. cynomolgi hepatic forms, observed in vitro in primary hepatocytes from the
natural host Macaca fascicularis, can be distinguished from similar forms seen in P. falciparum-infected human primary
hepatocytes by the differential action of selected anti-malarial drugs. Whereas atovaquone and pyrimethamine are active on
all the dividing hepatic forms observed, the P. cynomolgi slow growing forms are highly resistant to treatment by these
drugs, but remain susceptible to primaquine.
Conclusion: Resistance of the non-dividing P. cynomolgi forms to atovaquone and pyrimethamine, which do not prevent
relapses, strongly suggests that these slow growing forms are hypnozoites. This represents a first step towards the
development of a practical medium-throughput in vitro screening assay for novel hypnozoiticidal drugs.
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Introduction
In mammalian hosts, malaria infection is initiated by the
inoculation of Plasmodium sporozoites by an infected anopheline
mosquito. These parasite forms then make their way to the liver
where they specifically invade hepatocytes, the host cells
permissive to full maturation leading to the production of
merozoites that initiate the erythrocytic cycle. In most Plasmodium
species, invasion of the hepatocyte by the sporozoite proceeds
seamlessly to the development of the hepatic parasite culminating
in the release of merozoites into the blood stream. The minimum
time between the infective bite and the blood infection varies with
the parasite species (2 to 15 days). However, in five parasite
species, three in southeast Asian monkeys (P. cynomolgi, P. fieldi and
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P. simiovale) and two in humans (P. vivax and P. ovale), a subset of the
sporozoites that have invaded the hepatocyte do not develop
beyond the early hepatic trophozoite stage, but remain in a state of
latency in which they can persist for many years [1,2]. These
forms, called hypnozoites, resume their development to generate
infective merozoites many weeks, months or years later, though
the timing and trigger for this ‘‘re-activation’’ remains mysterious.
The hypnozoites probably provide a significant evolutionary
advantage, particularly in temperate climates, as they effectively
extend the duration of infection and, thus the opportunities to
transmit successfully via mosquitoes to new hosts.
The demonstration of hypnozoites in P. cynomolgi-infected rhesus
macaques in the early 1980’s provided an explanation for the
relapses observed during infections with these five parasite species
[3]. A relapse is a blood stage episode that can occur after full
clearance of parasites from the erythrocytic parasites (naturally or
via treatment) from a primary or a recrudescent episode. In P.
vivax, relapses are often observed regularly over many months and
even years after the infectious mosquito bite. A similar pattern is
also observed for P. ovale. Moreover, some temperate P. vivax
strains produce sporozoites that nearly all transform into
hypnozoites such that the primary blood infection is only observed
many months after the infective mosquito bite, when some of the
hypnozoite reactivate [1,2]. Given that P. vivax is the most widely
distributed of the four species of malaria parasites specific to
humans and the most prevalent, except for sub-Saharan Africa
where P. falciparum dominates and P. ovale infections are common
[4], the occurrence of hypnozoites/relapses adds to their
morbidity burden and makes these species especially difficult to
eradicate.
Only one antimalarial drug capable of eliminating all liver
stages including hypnozoites, the 8-aminoquinoline primaquine, is
currently available [5,6]. Its short half-life in the serum necessitates
a lengthy treatment regimen that is not conducive to good
adherence. Another recently developed 8-aminoquinoline with a
longer half-life, tafenoquine, is equally effective against hypno-
zoites. However, the major shortcoming of primaquine and
tafenoquine is that administration to persons with glucose-6-
phosphate dehydrogenase deficiency (G6PD) is associated with a
high risk of severe haemolytic anaemia. This precludes their
widespread use because carriage of this genetic trait is common in
the majority of the populations in P. vivax and P. ovale endemic
areas.
The revival of eradication as the ultimate goal of malaria
control programmes and the rediscovery that the clinical and
socio-economic burdens of vivax malaria rival those of falciparum
malaria, makes it imperative to develop novel compounds able to
eliminate hypnozoites. Such a drug discovery programme cannot
be currently envisaged simply because the only model available to
screen for activity against hypnozoites is the P. cynomolgi sporozoite
infection in rhesus monkeys. This host-parasite combination,
whose development was initiated in 1944, remains the acknowl-
edged biological and chemotherapeutic model for P. vivax
infections, including erythrocytic and hepatic stages [7,8,9,10].
However, an in vitro model is necessary in order to screen large
numbers of new compounds for hypnozoiticidal activity. Hopes to
achieve this were raised with the establishment of in vitro cultured
hepatic stages of P. vivax [11,12] and then P. cynomolgi [13,14] in
their respective primary host hepatocytes. In parallel, P. vivax
hepatic stage maturation was obtained in the hepatoma cell line
HepG2-A16 [15]. Observation of non-dividing P. vivax forms in
HepG2-A16 cells when most hepatic forms have developed to
form mature schizonts (5–8 days after sporozoite inoculation),
prompted the suggestion that these corresponded to hypnozoites
[15]. This was re-enforced when the proportion of these non-
dividing forms correlated with the expected proportion of
hypnozoites to dividing hepatic parasites for different P. vivax
strains, namely in equal numbers from tropical strains and with a
predominance of hypnozoites from temperate strains [16,17].
However, these morphological observations alone are of insuffi-
cient weight to establish the actual nature of the non-dividing
forms observed as hypnozoites. Failure of hepatic parasites to
reach to first mitotic division might be due to other factors, such as
defective sporozoites, or failure to thrive in a metabolically
unsuitable host cell, or in a sub-optimal culture environment.
Indeed, cultured hepatic parasites, as well as those found in vivo
under natural conditions of infection, are often asynchronous, with
large variations in size and developmental stage as cultivation
progresses. Furthermore, in our experience small uninuclear
hepatic forms are equally regularly observed along with mature
hepatic schizonts in primary hepatocyte or hepatoma cell cultures
infected with sporozoites from Plasmodium species that do not form
hypnozoites, such as P. falciparum or P. berghei.
We have recently proposed that the differential susceptibility of
normal hepatic forms and of hypnozoites to defined anti-malarial
drugs might serve to indicate the presence of hypnozoites in
infected hepatocyte cultures [18]. This was tested in parallel
cultures of P. falciparum and P. cynomolgi infections in their host’s
respective primary hepatocytes, because this provides a means to
establish if the non-dividing parasites obtained from the relapsing
species (P. cynomolgi) and the non-relapsing species (P. falciparum) are
biologically distinct.
Results and Discussion
Slow growing and normally developing hepatic forms
occur in hepatocyte cultures
Primary hepatocytes were isolated from liver segments obtained
from humans or from Macaca fascicularis, the natural host of P.
cynomolgi [1,2]. The primary hepatocyte cultures were infected with
P. falciparum or P. cynomolgi sporozoites respectively, and then
maintained for 11 days. Each day some wells from the cultures
were fixed and the numbers and sizes of the hepatic forms present
were measured. The hepatic forms were visualized using two
stains: DAPI that reveals the nuclei and an antibody raised against
a P. falciparum heat shock protein 70.1 (HSP70.1) [19], which
recognizes both P. falciparum and P. cynomolgi parasites. HSP70.1
expression in hepatic stages is initiated about three hours after
hepatocyte invasion and is maintained until full maturation of the
hepatic schizont.
As expected, from Day 3 post-inoculation onwards, most P.
falciparum and about half of P. cynomolgi hepatic forms obtained
developed normally (parasite nuclear division and size increase),
however in a proportion of the infected hepatocytes the parasites
remained uninucleate (Fig. 1) and did not grow beyond their size
on Day 1. The smaller uninucleate pre-erythrocytic (PE) forms
were termed PE-uni, while the maturing forms were termed mat-
PE. As the infection progressed, some differences were observed
between the P. falciparum and P. cynomolgi cultures (Fig. 2). Nearly
40% of the hepatic forms in the P. cynomolgi were of the PE-uni
type on Day 3 and these forms remained unchanged by Day 11, at
which time they represented nearly two thirds of the hepatic forms
as by that time nearly all developing forms had fully matured and
burst. In contrast, the P. falciparum PE-uni forms were fewer in
numbers from the outset and although their absolute numbers
remained constant between Day 5 and Day 9, they had
significantly declined by Day 11 (p,0.05, Mann-Whitney test).
When both cultures were stopped on Day 11, most of the
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remaining mat-PE forms were large mature hepatic schizonts each
with a large number of visible parasite nuclei. Similar proportions
of long-lived PE-uni forms were obtained when P. cynomolgi
sporozoites were used to infect cultured rhesus monkey (M. mulatta)
primary hepatocytes (data not shown).
Differential activity of selected antimalarial drugs
distinguished the two hepatic forms
The PE-uni observed in the P. falciparum (a non-hypnozoite
producing species) and in the P. cynomolgi (a hypnozoite producing
species) hepatic cultures are indistinguishable from the non-
dividing forms postulated to be hypnozoites that were observed in
cultured HepG2 cells infected with P. vivax strains of different
geographical origins [15,16,17,20].
In order to provide unequivocal proof that the PE-uni forms
observed in the P. cynomolgi (or P. vivax) hepatic cultures are indeed
hypnozoites, it would be necessary to observe after a suitable
period of latency (at least 3–4 weeks), a reactivation of the
maturation process that would lead to the release of merozoites.
This would be difficult for HepG2 cultures because beyond a week
of incubation, the multiplication of the hepatoma cells will
irrevocably lead to an unacceptable dilution of the few non-
dividing forms. This can be overcome by prior irradiation of the
HepG2 cells prior to inoculation with sporozoites, though it is not
clear that hypnozoites are capable of forming and/or being
reactivated in hepatoma cells. Primary hepatocytes do not divide
in culture, but maintaining their viability beyond a few weeks has
proven difficult.
Given these limitations, we postulated that data consistent with
a hypnozoite identity for the P. cynomolgi PE-uni forms could be
derived by exploiting the contrasting activities of three current
anti-malarial drugs against hypnozoites [18]. Pyrimethamine (an
inhibitor of dihydrofolate reductase), atovaquone (an inhibitor of
the mitochondrial cytochrome c) and primaquine (putatively a
mitochondrial inhibitor), have all been demonstrated to fully
Figure 1. Slow growing and normally developing pre-erythrocytic (PE) forms. Two types of hepatic parasites can be clearly distinguished
from days 5 post-infection onwards, in in vitro cultured human or M. fascicularis primary hepatocytes infected with P. falciparum or P. cynomolgi
sporozoites, respectively. The representative photomicrographs were made on cultures fixed on Day 5 and Day 11 post-infection. The parasite and
host nuclei are stained with DAPI (blue), while the parasites are labelled by an antibody specific to the HSP70 of the two parasite species (green).
Mature PE forms (Mat-PE) and uninucleate small PE forms (PE-uni) are clearly distinguishable.
doi:10.1371/journal.pone.0018162.g001
Figure 2. Maturation dynamics of cultured P. falciparum and P.
cynomolgi hepatic forms. The proportion of PE forms at different
stages of maturation (as assessed by the extent of nuclear division) is
presented for cultures of increasing age. Uninucleate parasite forms
correspond to the small forms (PE-uni) shown in Figure 1, while all
others correspond to the mat-PE forms. The data was representative of
three independent experiments.
doi:10.1371/journal.pone.0018162.g002
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inhibit normal hepatic stage parasites in vivo and in vitro
[10,21,22,23,24,25]. Only primaquine however, is able addition-
ally to eliminate hypnozoites [5,6].
Having established above that the PE-uni forms are most
evident between Day 5 and Day 9 of cultivation, during which
time their numbers remain stable for both P. falciparum and P.
cynomolgi, we obtained the IC50 values for these drugs against
the PE-uni and the mat-PE forms following exposure to the
drugs for three days from Day 5 to Day 8 (Fig. 3 and Table 1).
As expected, the two types of hepatic forms (mat-PE and PE-
uni) from both parasite species were eliminated with prima-
quine, with similar IC50 values (650 nM to 1166 nM,
equivalent to 0.3 mg/ml–0.53 mg/ml of the diphosphate salt).
In all cases, full inhibition was observed as the concentration
reached 110 mM (50 mg/ml), though it should be noted that M.
fascicularis hepatocytes viability decreased with exposure to
primaquine concentrations higher than 22 mM (10 mg/ml) as
assessed by MTT (TC50SH = 56 mM). By contrast, while both
pyrimethamine and atovaquone inhibited the development of
the mat-PE forms of both parasite species as well as the non-
dividing PE-uni of P. falciparum, the P. cynomolgi PE-uni forms
showed resistance to these drugs, displaying a 900-fold and a
20-fold increase in the IC50 values for atovaquone and
pyrimethamine, respectively.
The inhibition of the PE-uni forms by primaquine indicates that
they are metabolically active. However, the resistance of the P.
cynomolgi PE-uni forms to atovaquone and pyrimethamine, as
compared to the sensitivity of the P. falciparum PE-uni forms to
these drugs, suggests that the metabolism of the cultured non-
dividing hepatic parasites differs between the two species. The
concordance of these observations in vitro with the known inability
of pyrimethamine and atovaquone to prevent relapses and thus,
eliminate hypnozoites in vivo, strongly suggests that the majority of
the P. cynomolgi PE-uni forms we observed in culture represent
hypnozoites.
Since the ultimate aim is to develop a viable screening assay to
identify novel hypnozoitocidal drugs, we modified the assay to
include a PE-uni selection step before testing for primaquine
activity against these forms. This was achieved by treating P.
cynomolgi hepatic cultures with atovaquone between Day 5 and Day
8. Subsequent to this, most of the hepatic parasites present in the
cultures were the PE-uni forms, and these forms persisted
unaffected whether atovaquone treatment was withdrawn or
maintained another three days, up to Day 10. By contrast, their
numbers were significantly diminished by exposure to primaquine
on Day 8 to Day 10 (Fig. 4).
Conclusions
Here we demonstrate that the non-dividing P. cynomolgi and P.
falciparum hepatic forms that are observed in cultured primary
hepatocytes isolated from their respective natural hosts are distinct.
The higher PE-uni numbers observed for P. cynomolgi, their
maintenance in undiminished numbers after 10 days of cultiva-
tion, and their resistance to inhibition by atovaquone and
pyrimethamine distinguishes them from the P. falciparum PE-uni
forms. These observations, when associated to susceptibility to
elimination by primaquine and to the contrasting relapse patterns
of sporozoite-induced P. cynomolgi infections in rhesus monkeys
after primaquine or pyrimethamine treatment, provide compelling
support for the hypothesis that these in vitro PE-uni forms actually
represent hypnozoites. In any case, the PE-uni forms seem to
provide a hypnozoite surrogate suitable for drug discovery
programs. Given the long-established biological and chemother-
apeutic equivalence of P. vivax and P. cynomolgi infections [8,9,10],
we consider it likely that similar PE-uni forms will be observed for
P. vivax. It would also be reasonable to suggest that the non-
Figure 3. Dose-response curves for primaquine, atovaquone and pyrimethamine against the distinct hepatic forms observed for P.
falciparum and P. cynomolgi. The infected primary hepatocyte cultures were exposed to the varying drug concentrations from Day 5 to Day 8 post-
inoculation and fixed on D8. The curves obtained for the PE-uni forms are presented in red, while those for the Mat-PE forms are presented in black.
The data was representative of two independent assays for pyrimethamine (for both parasite species) and for primaquine (P. falciparum); and of three
independent experiments for atovaquone (both parasite species) and primaquine (P. cynomolgi). *, p,0.05.
doi:10.1371/journal.pone.0018162.g003
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dividing P. vivax forms initially observed in HepG2-A16 cells in
mid 1980 [15,16] and very recently [20] could also represent
hypnozoites. Nonetheless, this would need a validation similar to
the one presented here because it is not known whether hepatoma
cells lines present a suitable environment for hypnozoite formation
and eventual reactivation.
The work described here represents a first significant step
towards the development of a screening assay aimed at the
discovery of novel hypnozoiticidal compounds. The use of P.
cynomolgi for this endeavour is justified by the fact that the requisite
provision of a constant supply of sporozoites from the same strain,
or eventually clone, can be achieved without the necessity to infect
chimpanzees as is the case for P. vivax [20], or rely on patients
infected by different P. vivax strains. On the other hand, if medium-
throughput screening programs are envisaged it would be
necessary to have access to easy-to-culture cell lines that are at
least as susceptible to sporozoite infection as the primary
hepatocytes isolated from monkey liver segments. Finally, the
availability of a potential in vitro hypnozoite model opens the way
to conduct detailed investigations into the nature and mechanisms
of latency in Plasmodium parasites, a hitherto closed avenue of
fundamental biological interest.
Methods
Ethics Statement
Human hepatocytes were isolated from liver segments taken
after oral informed consent from adult patients undergoing partial
hepatectomy as part of their medical treatment (Service de
Chirurgie Digestive, He´pato-Bilio-Pancre´atique et Transplanta-
tion He´patique, Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France). The
collection and use of this material for the purposes of the study
presented here were undertaken in accordance with French
national ethical guidelines under Article L. 1121-1 of the ‘‘Code de
la Sante´ Publique’’. Given that the tissue samples are classed as
surgical waste, that they were used anonymously (the patient’s
identity is inaccessible to the researchers), and that they were not
in any way genetically manipulated, article L. 1211-2 stipulates
that their use for research purposes is allowed provided that the
patient does not express any opposition to this to the surgeon prior
to surgery after being informed of the nature of the research in
which they might be potentially employed. Within this framework,
the collection and use of this material was furthermore approved
by the Institutional Review Board (Comite´ de Protection des
Personnes) of the Centre Hospitalo-Universitaire Pitie´-Salpeˆtrie`re,
Assistance Publique-Hoˆpitaux de Paris, Paris, France.
All Macaca mulatta in this study were captive bred for research
purposes. BPRC housing and animal care procedures are in
compliance with Dutch law on animal experiments, European
directive 86/609/EEC, and with the ‘‘Standard for Humane Care
and Use of Laboratory Animals by Foreign Institutions’’,
identification number A5539-01, provided by the Department of
Health and Human Services of the US National Institutes of
Health (NIH). The local independent ethical committee, consti-
tuted according to Dutch law on animal experiments, approved
the study protocols prior to start of the experiments. Adult
cynomolgus macaques (Macaca fascicualris) were imported from
Mauritius and housed in the facilities of the Centre d’Energie
Atomique (CEA) (Fontenay-aux-Roses, France). Non-human
primates (NHP, that includes M. fascicularis) are used at the CEA
in accordance with French national regulation and under the
inspections of national veterinary inspectors. The CEA is in
compliance with Standards for Human Care and Use of
Laboratory Animals (Animal Welfare Assurance, OLAW number
#A5826-01). The use of NHP at CEA is in accordance with
recommendation of the Weatherall report as follows: NHP are
used at CEA only when no other models (in vitro or in vivo) are
suitable for the aims of the project (recommendation nu1); the
study is in the field of infectious diseases (recommendation nu2),
Plasmodium physio-pathology; NHP are breed following the
recommendation of the ETS123 and in accordance with the
newly published Eureopean Directive (2010/63) (recommendation
nu9). It should be stressed that none of the animal were specifically
used for this work, since the liver fragments were collected at
necropsy from animals that were euthanized in the course of
unrelated studies, thus no suffering was specifically associated with
the surgical procedure to obtain the liver fragments. This
approach is fully in accordance with the 3R and reduces the
number of animal used. Animal suffering avoidance and
refinement of procedures are included in CEA aims. The animals
were used under the supervision of the veterinarians in charge of
Table 1. IC50 values for selected drugs against the different hepatic parasites.
Primaquine IC50 in mM (95% CI) Atovaquone IC50 in nM (95% CI) Pyrimethamine IC50 in mM (95% CI)
PE-uni mat-PE PE-uni mat-PE PE-uni mat-PE
P. cynomolgi 0.80 (0.55–1.17) 0.65 (0.50–0.85) 1997 (1638–2435) 2.13 (1.38–3.30) 20.31 (14.95–27.60) 1.03 (0.84–1.25)
P. falciparum 0.69 (0.51–0.94) 1.17 (0.80–1.70) 6.09 (2.67–13.94) 3.48 (2.21–.47) 0.94 (0.65–.37) 1.53 (1.18–1.99)
doi:10.1371/journal.pone.0018162.t001
Figure 4. Selection of P. cynomolgi PE-uni forms prior to
screening for hypnozoiticidal activity. Cultures were treated with
atovaquone (ATQ) at 67 ng/ml (182 nM) for three days starting on Day
5 post-inoculation in order to eliminate the mat-PE parasites.
Subsequently the cultures were either left untreated, treated for a
further two days with ATQ (as above), or primaquine (PQ) at 10 mg/ml
(22 nM). The cultures were then stopped by methanol fixation on Day
10 and the hepatic forms present enumerated. The data was
representative of three independent experiments. *, p,0.05.
doi:10.1371/journal.pone.0018162.g004
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the animal facility and the protocols employed were reviewed by the
Ethical Animal Committee of the CEA. During ethical review, the
end points and analgesia were reviewed and optimised. Experi-
mental procedures were conducted in strict accordance with the
recommendations of the European guidelines for the care and use of
laboratory animals (European directive 86/609/EEC, OJ, L358,
December 18, 1986). In addition, the CEA facilities was accredited
(assurance identification number #A5826-01) by the National
Institute of Health (USA) Office for Laboratory Animal Welfare
(OLAW). The protocols and the use of hepatocytes for the purpose
of the work described herein were approved by the Ethical Animal
Committee of the CEA (Permit Number A 92-032-02).
Drugs
Primaquine, 8-(4-amino-1-methylbutylamino)-6-methoxyquino-
line diphosphate salt, and pyrimethamine, 5-(4-chlorophenyl)-6-
ethyl-2,4-pyrimidinediamine, were purchased from Sigma-Aldrich
St Louis, MO, USA (P9504 and P771, respectively); atovaquone,
trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalene-
dione was purchased from Laboratoire GlaxoSmithKline, France.
Sporozoites
P. falciparum (strain NF54) sporozoites were obtained from
infected Anopheles stephensi salivary glands collected on days 14–21
after an infective blood meal on a membrane-based feeder system
(Department of Medical Microbiology, University Medical Centre
St. Radboud, Nijmegen, The Netherlands). Plasmodium cynomolgi
(M strain) sporozoites were obtained from infected Anopheles
stephensi salivary glands collected on days 14–35 after an infective
blood meal on blood from a Macaca mulatta, infected with blood
stage P. cynomolgi parasites using membrane-based glass feeders
(Biomedical Primate Research Centre, Rijswijk, The Netherlands).
Primary hepatocytes
Human hepatocytes were isolated from liver segments taken from
adult patients in the course of partial hepatectomy (Service de
Chirurgie Digestive, He´pato-Bilio-Pancre´atique et Transplantation
He´patique, Hoˆpital Pitie´-Salpeˆtrie`re, Paris, France). Simian hepa-
tocytes were isolated from Macaca fascicularis or M. mulatta liver
segments (provided by Roger Le Grand, commissariat a` l’Energie
Atomique CEA, Fontenay-aux-Roses, France, or by Clemens H M
Kocken, Biomedical Primate Research Centre, Rijswijk, The
Netherlands, respectively) taken from healthy animals. The primary
hepatocytes were isolated using two-step enzymatic perfusion as
previously described [26]. Briefly, the hepatic segments were
successively perfused with HBSS-HEPES buffer and with collage-
nase (C5138, Sigma-Aldrich St Louis, MO, USA), and then
dissociated. Viable cells were recovered after centrifugation over a
37% Percoll layer. The isolated simian primary hepatocytes that
were obtained were immediately cryopreserved. On the days when
human liver segments became available, and when the viability of
the primary hepatocytes isolated from these was deemed satisfactory
for infection with parasites, an aliquot of the M. fascicularis primary
hepatocytes was thawed and the two host cell types were separately
seeded and incubated for 24 h before infection.
The primary hepatocytes were seeded at a density of
8.36104 cells per well allowing cell confluence in mclear plate
Black 96 wells (Greiner Bio-one, France), or 2.16105 cells per well
in Lab-Tek 8-chambers slides, in both cases coated with rat tail
collagen I (Becton Dickinson, Le Pont de Claix, France) in
complete medium: William’s medium E (Gibco, Cergy-Pontoise,
France) supplemented with 10% foetal calf serum (Perbio),
561025 M hydrocortisone hemisuccinate (Upjohn SERB Labor-
atoire), 5 mg/ml Insulin (Sigma), 2 mM L-Glutamine (25030-024,
Gibco), 0.02 U/ml–0.02 mg/ml Penicillin-streptomycin (15140-
122, Life Technologies) and incubated at 37uC, 5% CO2 for 24 h
before infection.
Pre-erythrocytic cultures and drug assays
After isolation, the P. falciparum or P. cynomolgi sporozoites were
suspended in complete medium and added to their respective
host’s primary hepatocyte cultures. For drug assays, 36104
sporozoites were added to each well, or 16105 P. cynomolgi
sporozoites for cultures initiated in Lab-Tek 8-chambers slides.
Infected cultures were fixed with cold 100% methanol on Days 1,
3, 5, 7, 9 and 11 post-infection in order to count and measure the
size of the P. cynomolgi or P. falciparum pre-erythrocytic (PE) forms
obtained. For the drug assays, the antimalarial drugs were added
at different concentrations to complete medium. Infected cells
were exposed to the drug for 3 days from Day 5 until fixation at
Day 8 post-infection. In a second set of experiments, PE-uni
selection was included by treatment of P. cynomolgi hepatic cultures
with atovaquone at 67 ng/ml (182 nM) between Day 5 and Day
8. This was followed by a 2 days treatment with either the same
concentration of ATO or with PQ at 10 mg/ml (22 nM), until
fixation at Day 10 post-infection. In all cases, the medium
containing the drug was renewed daily during treatment. Assays
for each drug were generally conducted in two or three
independent experiments. In an individual experiment, each
concentration was tested in duplicate or triplicate wells.
Hepatic parasites were enumerated by immunofluorescence
analysis. Briefly, following fixation, the parasites were specifically
labelled with a mouse polyclonal serum raised against the P.
falciparum heat shock protein 70.1 (PfHSP70.1) obtained after
immunization with the recombinant protein. This serum also
cross-reacts with P. cynomolgi HSP70. The labelled parasites were
visualized with Alexa 488-conjugated goat anti-mouse immuno-
globulin (Invitrogen). Parasite and host cell nuclei were stained
with 1 mg/ml of diamidino-phenylindole (DAPI; Sigma). Parasites
were enumerated by examination of the cultures under a
fluorescence microscope at 2006 magnification (Leica DMI
4000 B). Photomicrographs were obtained using a confocal
Olympus BX61 microscope at 6006 magnification on cells
cultures in Lab-Tek 8-chambers slides.
The cytotoxicity of the anti-malarial drugs was evaluated on M.
fascicularis hepatocytes treated as for the drug activity assays,
through the colorimetric methylthiazolyldiphenyl-tetrazolium
bromide test (MTT) [27]. Briefly, the primary hepatocytes were
exposed to various concentrations of drug and three days later, a
100 ml MTT solution (500 mg/mL) was added in each well. After
4 h of incubation at 37uC, the plates were read in a
spectrophotometer (540 nm absorbance wavelength) and the
results were expressed as percentage of cellular viability compared
to the non-treated control.
Data analysis
Dose-response curves and inhibitory concentrations 50% (IC50)
were calculated by non-linear regression analysis using GraphPad
Prism software with the data previously normalized to the
untreated controls. Mean parasite numbers were compared using
the Mann-Whitney non-parametric test. A p-value of less than
0.05 was considered to be statistically significant in the tests.
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